Ke Sun

Dr. Ke Sun


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HZHaihong Zhao
Haihong Zhao
LWLina Wu
Lina Wu
JDJiemin Dai
Jiemin Dai
KSKe Sun
Ke Sun
ZZZhenguo Zi
Zhenguo Zi
LZLiwen Zhang
Liwen Zhang
Background: Ovarian cancer (OC) is a highly aggressive gynecological malignancy prevalent worldwide. Most OC cases are typically diagnosed at advanced stages, which has led to a 5-year overall survival rate of less than 35% following conventional treatment. Furthermore, immune checkpoint inhibitor therapy has shown limited efficacy in the treatment of patients with OC, and CAR-T therapy has also demonstrated modest results owing to inadequate T cell infiltration. Therefore, novel strategies must be developed to enhance T cell persistence and trafficking within the OC tumor microenvironment. Methods: In this study, we developed a novel adoptive T-cell therapy for ovarian cancer based on a chimeric antigen receptor structure. We used a ligand-receptor binding motif to enhance the therapeutic effect of targeting CA125. Since mesothelin can naturally bind to CA125 with high affinity, we concatenated the core-binding fragment of mesothelin with the 4-1BB and CD3ζ signal fragments to assemble a novel CA125-targeting chimeric receptor (CR). The CAR structure targeting CA125 derived from the 4H11 antibody was also constructed. CR- and CAR-encoding RNA were electroporated into T cells to evaluate their antitumor activity both in vitro and in vivo. Results: While CR-T or CAR-T cells exhibited moderate activity against two ovarian cancer cell lines, T cells co-expressing CR and CAR exhibited a superior killing effect compared to T cells expressing either CR or CAR alone. Furthermore, upon interaction with ovarian tumors, the ability of CR and CAR T cells to release activation markers and functional cytokines increased significantly. Similarly, CR and CAR co-expressing T cells persistently controlled the growth of transplanted ovarian cancer tumors in NSG mice and significantly prolonged the overall survival of tumor-challenged mice. Transcriptome sequencing revealed that the survival and cytotoxicity of T cells co-expressing CR and CAR were significantly altered compared with those of T cells expressing either CR or CAR. Conclusion: Our findings demonstrate that CA125 targeting CR and CAR can synergistically kill ovarian cancer cells, indicating that CA125 targeting by the two binding motifs simultaneously in tumors may improve the therapeutic outcomes of ovarian cancer treatment.

23 July 2024 in Heliyon
Verified
Journal Article
Open access
RCRujun Chen
Rujun Chen
YHYating Huang
Yating Huang
KSKe Sun
Ke Sun
FDFuyun Dong
Fuyun Dong
XWXiaoqin Wang
Xiaoqin Wang
HFHe Fei
He Fei
Ovarian cancer (OCa) is a common malignancy in women, and the role of cuproptosis and its related genes in OCa is unclear. Using the GSE14407 dataset, we analyzed the expression and correlation of cuproptosis-related genes (CRGs) between tumor and normal groups. From the TCGA-OV dataset, we identified 20 cuproptosis-related long non-coding RNAs (CuLncs) associated with patient survival through univariate Cox analysis. OCa patients were divided into early-stage and late-stage groups to analyze CuLncs expression. Cluster analysis classified patients into two clusters, with Cluster1 having a poorer prognosis. Significant differences in “Lymphatic Invasion” and “Cancer status” were observed between clusters. Seven CRGs showed significant expression differences, validated using the human protein atlas (HPA) databases. Immune analysis revealed a higher ImmuneScore in Cluster1. GSEA identified associated signaling pathways. LASSO regression included 11 CuLncs to construct and validate a survival prediction model, classifying patients into high-risk and low-risk groups. Correlations between riskScore, Cluster phenotype, ImmuneScore, and immune cell infiltration were explored. Cell experiments showed that knocking down AC023644.1 decreases OCa cell viability. In conclusion, we constructed an accurate prognostic model for OCa based on 11 CuLncs, providing a basis for prognosis assessment and potential immunotherapy targets.

8 July 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
RCRujun Chen
Rujun Chen
QSQiran Sun
Qiran Sun
JCJina Chen
Jina Chen
YHYating Huang
Yating Huang
YYYing Yang
Ying Yang
FDFuyun Dong
Fuyun Dong
Background Ovarian cancer (OC) has a dismal prognosis due to late diagnosis and platinum resistance, with the molecular mechanisms linking cuproptosis, lncRNAs, and the tumor microenvironment (TME) remaining poorly defined. LncRNA ENSG00000253374 was previously identified as a prognostic biomarker for OC, while its correlation with cuproptosis and platinum resistance remains unclear. Methods Integrated bulk RNA-seq (TCGA-OV) and single-cell RNA-seq (GSE300897) analyses were performed, combined with in vitro CCK-8 assays, intracellular Cu⁺ detection, survival analysis, WGCNA, pseudotime trajectory, CellChat, virtual knockout, and functional enrichment analyses. OC cells with ENSG00000253374 knockdown were subjected to cuproptosis induction, and GLS-centered co-expression patterns and TME features were characterized. Results ENSG00000253374 knockdown correlates with altered cellular response to cuproptosis induction, and shows close expression correlation with GLS. The ENSG00000253374–GLS correlated signature is linked to abnormal glutamine metabolism, cell cycle and stemness features, and is associated with immunosuppressive myeloid differentiation and enhanced pro-resistance intercellular communication that correlate with platinum refractoriness. WGCNA constructed a GLS-centered co-expression network enriched in immune and stromal remodeling pathways; in silico GLS perturbation predicted altered stemness, angiogenesis and apoptotic signaling signatures. Elevated GLS expression in tumor and stromal cells coincides with stronger TME crosstalk and dominant M2 macrophage populations. Conclusion LncRNA transcripts of the ENSG00000253374 locus are associated with platinum-resistant ovarian cancer phenotypes via a GLS-related correlative signature, alongside disrupted cuproptosis and metabolic-immune remodeling. Our in vitro assays reflect overall transcriptional activity of this genomic locus rather than single splice variant function. ENSG00000253374 and GLS may serve as candidate prognostic biomarkers. Combinatorial interventions targeting this correlative axis together with cuproptosis inducers or immune modulators could provide potential strategies to relieve platinum resistance in OC.